An association study of 43 SNPs in 16 candidate genes with atorvastatin response - The Pharmacogenomics Journal
- ️Sasiela, W J
- ️Tue Aug 16 2005
Gresser U, Gathof BS . Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke—comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004; 9: 1–17.
Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992; 85: 1293–1303.
Maitland-van der Zee AH, Klungel OH, Stricker BHC, Verschuren WMM, Kastelein JJP, Leufkins HGM et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002; 163: 213–222.
Kajinami K, Takekoshia N, Brousseau ME, Schaefer EJ . Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004; 177: 219–234.
Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM . Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291: 2821–2827.
Rieder MJ, Taylor SL, Clark AG, Nickerson DA . Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999; 22: 59–62.
Tanaka C, Kamide K, Takiuchi S, Miwa Y, Yoshii M, Kawano Y et al. An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms. Hypertens Res 2003; 26: 301–306.
Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C . Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001; 88: 265–269.
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ . Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004; 93: 1046–1050.
Ioannidis JPA, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG . Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361: 567–571.
Campbell H, Rudan I . Interpretation of genetic association studies in complex disease. Pharmacogenom J 2002; 2: 349–360.
Daly AK, King BP . Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 247–252.
Krynetski EY, Evans WE . Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharmaceut Res 1999; 16: 342–349.
Sindrup SH, Brosen K . The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5: 335–346.
Kaplan RC, Bhalodkar NC, Brown Jr EJ, White J, Brown DL . Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications. Prev Med 2004; 39: 1249–1255.
Thompson JF, Lira ME, Durham LK, Clark RW, Bamberger MJ, Milos PM . Polymorphisms in the CETP gene and association with CETP mass and HDL levels. Atherosclerosis 2003; 167: 195–204.
Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM, Schaefer EJ . ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res 2004; 45: 653–656.
Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AN, Ballantyne CM . Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin. J Am Coll Cardiol 2000; 35: 89–95.
Lahoz C, Pena R, Mostaza JM, Jimenez J, Subirats E, Pinto X et al. Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 2003; 168: 289–295.
Ojala JP, Helve E, Ehnholm C, Aalto-Setala K, Kontula KK, Tikkanen MJ . Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 1991; 230: 397–405.
Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158: 183–193.
van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in Type 2 diabetes. Diabetes Care 2003; 26: 1216–1223.
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ . Cyp3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93: 104–107.
Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF et al. Lipid lowering response to statins is affected by Cyp3A5 polymorphism. Pharmacogenetics 2004; 14: 523–525.
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ . A promoter polymorphism in cholesterol 7a-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 2005; 180: 407–415.
Salazar LA, Hirata MH, Quintao ECR, Hirata RDC . Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 2000; 14: 125–131.
Lahoz C, Pena R, Mostaza JM, Laguna F, Garcia-Iglesias MF, Taboada M et al. The –514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 2005 (in press).
Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T . Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75: 415–421.